Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns. The post Genmab to Pay $8B to Get Its Hands on Merus Head & Neck Cancer Drug With Blockbuster Potential appeared first on MedCity News.
Genmab to Pay $8B to Get Its Hands on Merus Head & Neck Cancer Drug With Blockbuster Potential
